Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer

Abstract

Introduction

Carcinogenesis is driven by an array of complex genomic patterns; these patterns can render an individual resistant or sensitive to certain chemotherapy agents. The Personalized Oncogenomics (POG) project at BC Cancer has performed integrative genomic analysis of whole tumour genomes and transcriptomes for over 700 patients with advanced cancers, with an aim to predict therapeutic sensitivities. The aim of this study was to utilize the POG genomic data to evaluate a discrete set of biomarkers associated with chemo-sensitivity or-resistance in advanced stage breast and colorectal cancer POG patients.

Methods

This was a retrospective multi-centre analysis across all BC CANCER sites. All breast and colorectal cancer patients enrolled in the POG program between July 1, 2012 and November 30, 2016 were eligible for inclusion. Within the breast cancer population, those treated with capecitabine, paclitaxel, and everolimus were analyzed, and for the colorectal cancer patients, those treated with capecitabine, bevacizumab, irinotecan, and oxaliplatin were analyzed. The expression levels of the selected biomarkers of interest (EPHB4, FIGF, CD133, DICER1, DPYD, TYMP, TYMS, TAP1, TOP1, CKDN1A, ERCC1, GSTP1, BRCA1, PTEN, ABCB1, TLE3, and TXNDC17) were reported as mRNA percentiles.

Results

For the breast cancer population, there were 32 patients in the capecitabine cohort, 15 in the everolimus cohort, and 12 in the paclitaxel cohort. For the colorectal cancer population, there were 29 patients in the bevacizumab cohort, 12 in the oxaliplatin cohort, 29 in the irinotecan cohort, and 6 in the capecitabine cohort. Of the biomarkers evaluated, the strongest associations were found between Bevacizumab-based therapy and DICER1 (P = 0.0445); and between capecitabine therapy and TYMP (P = 0.0553).

Conclusions

Among breast cancer patients, higher TYMP expression was associated with sensitivity to capecitabine. Among colorectal cancer patients, higher DICER1 expression was associated with sensitivity to bevacizumab-based therapy. This study supports further assessment of the potential predictive value of mRNA expression of these genomic biomarkers.

Keywords

Personalized oncogenomics chemosensitivity chemoresistance breast cancer colorectal cancer

Get full access to this article

View all access options for this article.

References

Laskin

Marra

Personalized oncogenomics (POG) program of British Columbia, https://clinicaltrials.gov/ct2/show/NCT02155621 (2014, accessed 9 August 2016).

International Agency for Research on Cancer. Global cancer facts & figures. 3rd ed. Atlanta: American Cancer Society, 2012.

Canadian Cancer Society. Canadian cancer statistics publication, www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on (2017, accessed 23 June 2017).

Silver

Livingston

DM.

Mechanisms of BRCA1 tumor suppression. Cancer Discov 2012; 2: 679–684.

Zhao

, et al. Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. Eur Rev Medicl Pharmacol Sci 2016; 20: 1993–2003.

Zhang

Geng

Talmon

, et al. MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem 2015; 290: 6215–6225.

Sawers

Ferguson

Ihrig

, et al. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Br J Cancer 2014; 111: 1150–1158.

Arai

Miyoshi

Kim

, et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 2008; 34: 734–738.

Zhai

Zhi

, et al. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7. Tumour Biol 2014; 35: 8883–88891.

10.

Samimi

Ring

Ross

, et al. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma. Cancer Epidemiol Biomarkers Prev 2012; 21: 273–279.

11.

Zhang

Wang

, et al. STAT3-dependent TXNDC17 expression mediates taxol resistance through inducing autophagy in human colorectal cancer cells. Gene 2016; 584: 75–82.

12.

Koopman

Venderbosch

van Tinteren

, et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009; 45: 1999–2006.

13.

Guijarro-Munoz

Sanchez

Martinez-Martinez

, et al. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol 2013; 30: 572.

14.

Varol

Yildiz

Salman

, et al. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. Tumori 2014; 100: 370–376.

15.

Jandu

Aluzaite

Fogh

, et al. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer 2016; 16: 34.

16.

André

Hurvitz

Fasolo

, et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 2016; 34: 2115–2124.

17.

Butterfield

Kreitzman

Thiessen

, et al. JAGuaR: junction alignments to genome for RNA-seq reads. PLoS One 2014; 9: e102398.

18.

Mortazavi

Williams

McCue

, et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621–628.

19.

Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.

20.

Yang

, et al. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 2005; 280: 9330–9335.

21.

Mao

Gao

, et al. MicroRNA-107 contributes to post-stroke angiogenesis by targeting dicer-1. Sci Rep 2015; 5: 13316.

22.

Bruhn

Townsend

Khoon Lee

, et al. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. Int J Cancer 2014; 135: 731–741.

23.

Vincenzi

Zoccoli

Schiavon

, et al. Dicer and Drosha expression and response to bevacizumab-based therapy in advanced colorectal cancer patients. Eur J Cancer 2013; 49: 1501–1508.

24.

Karube

Tanaka

Osada

, et al. Reduced expression of dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005; 96: 111–115.

25.

Merritt

Lin

Han

, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359: 2641–2650.

26.

Chiosea

Jelezcova

Chandran

, et al. Up-Regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006; 169: 1812–1820.

27.

Andreetta

Puppin

Minisini

, et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 2009; 20: 265–271.

28.

Zhao

H-Y

Huang

Z-H

, et al. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. Anticancer Drugs 2012; 23: 534–542.